These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

490 related articles for article (PubMed ID: 18978515)

  • 1. Nationwide survey of palivizumab for respiratory syncytial virus prevention in Japanese children with congenital heart disease.
    Saji T; Nakazawa M; Harada K
    Pediatr Infect Dis J; 2008 Dec; 27(12):1108-9. PubMed ID: 18978515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recommendations for the use of palivizumab as prophylaxis against respiratory syncytial virus in infants with congenital cardiac disease.
    Tulloh R; Marsh M; Blackburn M; Casey F; Lenney W; Weller P; Keeton BR;
    Cardiol Young; 2003 Oct; 13(5):420-3. PubMed ID: 14694935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Palivizumab prophylaxis and hospitalization for respiratory syncytial virus disease in the Stockholm infant population, 1999 through 2002.
    Henckel E; Luthander J; Berggren E; Kapadia H; Naver L; Norman M; Bennet R; Eriksson M
    Pediatr Infect Dis J; 2004 Jan; 23(1):27-31. PubMed ID: 14743042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prophylaxis against respiratory syncytial virus in young children with cystic fibrosis.
    Giebels K; Marcotte JE; Podoba J; Rousseau C; Denis MH; Fauvel V; Laberge S
    Pediatr Pulmonol; 2008 Feb; 43(2):169-74. PubMed ID: 18085710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Current news about epidemiology of syncytial respiratory virus infection].
    Palumbo E
    Recenti Prog Med; 2008 May; 99(5):237-9. PubMed ID: 18581965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Prevention of respiratory syncytial virus infection by SYNAGIS (palivizumab)].
    Pin I; Pilenko C; Bost M
    Allerg Immunol (Paris); 2002 Dec; 34(10):371-4. PubMed ID: 12575622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physiologic risk factors for respiratory viral infections and immunoprophylaxis for respiratory syncytial virus in young children with congenital heart disease.
    Cabalka AK
    Pediatr Infect Dis J; 2004 Jan; 23(1 Suppl):S41-5. PubMed ID: 14730269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic analysis of palivizumab in infants with congenital heart disease.
    Yount LE; Mahle WT
    Pediatrics; 2004 Dec; 114(6):1606-11. PubMed ID: 15574622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants.
    Pedraz C; Carbonell-Estrany X; Figueras-Aloy J; Quero J;
    Pediatr Infect Dis J; 2003 Sep; 22(9):823-7. PubMed ID: 14506376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of palivizumab prophylaxis on respiratory syncytial virus hospitalizations in high risk Alaska Native infants.
    Singleton R; Dooley L; Bruden D; Raelson S; Butler JC
    Pediatr Infect Dis J; 2003 Jun; 22(6):540-5. PubMed ID: 12799511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial.
    Carbonell-Estrany X; Simões EA; Dagan R; Hall CB; Harris B; Hultquist M; Connor EM; Losonsky GA;
    Pediatrics; 2010 Jan; 125(1):e35-51. PubMed ID: 20008423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Use of palivizumab for the prevention of respiratory syncytial virus infections in children with congenital heart disease. Recommendations from the French Paediatric Cardiac Society].
    Chantepie A;
    Arch Pediatr; 2004 Nov; 11(11):1402-5. PubMed ID: 15519844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Palivizumab outcomes registry data from Spain: Infección Respiratoria Infantil por Virus Respiratorio Sincitial (IRIS) Study Group.
    Carbonell-Estrany X
    Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S55-7; discussion S57. PubMed ID: 12671453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry.
    Frogel M; Nerwen C; Cohen A; VanVeldhuisen P; Harrington M; Boron M;
    J Perinatol; 2008 Jul; 28(7):511-7. PubMed ID: 18368063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Palivizumab immunoprophylaxis: use in clinical practice, safety and beneficial effects in France].
    Pinquier D; Gouyon JB; Fauroux B; Mons F; Vicaut E; Bendjenana H; Rouffiac E; Marret S; Aujard Y
    Arch Pediatr; 2009 Nov; 16(11):1443-52. PubMed ID: 19767182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prophylaxis with palivizumab against respiratory syncytial virus infection in infants with congenital heart disease--who should receive it?
    Sunnegårdh J
    Acta Paediatr; 2006 Apr; 95(4):388-90. PubMed ID: 16720482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Guidelines for palivizumab prophylaxis: are they based on infant's risk of hospitalization for respiratory syncytial viral disease?
    Elhassan NO; Stevens TP; Sorbero ME; Dick AW; Guillet R; Hall CB
    Pediatr Infect Dis J; 2003 Nov; 22(11):939-43. PubMed ID: 14614363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of Palivizumab for prevention of hospitalization as a result of respiratory syncytial virus in infants with cystic fibrosis.
    Speer ME; Fernandes CJ; Boron M; Groothuis JR
    Pediatr Infect Dis J; 2008 Jun; 27(6):559-61. PubMed ID: 18434935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Guidelines for respiratory syncytial virus prophylaxis. An update].
    Carbonell-Estrany X; Quero Jiménez J
    An Esp Pediatr; 2002 Apr; 56(4):334-6. PubMed ID: 11927077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hospital admission of high risk infants for respiratory syncytial virus infection: implications for palivizumab prophylaxis.
    Heikkinen T; Valkonen H; Lehtonen L; Vainionpää R; Ruuskanen O
    Arch Dis Child Fetal Neonatal Ed; 2005 Jan; 90(1):F64-8. PubMed ID: 15613580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.